골반 종양 환자의 수술전 CA-125치의 진단적 의의 = Diagnostic Significance of Preoperative Serum CA-125 in Patients with Pelvic Masses

국문 초록 (Abstract)

상피성 난소암에서 주로 관찰되는 종양 표지물질인 CA-125는 종양의 악성여부와 수술 후 경과 관찰에 매우 유용하다고 알려져 있다. 이에 저자들은 1987년 7월부터 1995년 6월까지 인제대학교 부속 서울백병원 산부인과에 골반종양으로 진단되어 개복수술을 시행한 253명의 혈청 CA-125치를 분석하여 혈청 CA-125치가 수술 전 종양의 악성 여부를 구별할 수 있는 지를 알아보고자 이 연구를 시행하였다.

다국어 초록 (Multilingual Abstract)

To evaluate the diagnostic significance of tumor marker CA-125 in patients with pelvic masses, we measured preoperative serum CA-125 level in patients who underwent operations due to pelvic masses from July 1987 to June 1995. Serum CA-125 level of 35u/ml was determined as cut-off levels.
The following results were obtained
1.The histology of pelvic masses in 253 study patients consisted of 216 benign(85%) and malignant masses 37(15%)
2.CA-125 levels of the benign pelvic masses and malignant pelvic masses were 63.8u/ml and 231.2u/ml respectively. These differences were statistically significant. (p<0.05)
3.Using 35u/m1 as a cutoff, the false positivity of malignant ovarian tumor was 81.1%.
4.In contrast to the mean CA-125 concentration of mucinous adenocarcinoma of 154.8u/ml, the mean CA-125 concentration of non-mutinous adenocarcinoma was 266.5u/ml.
There was a statistically significant difference between these two groups.
5.Using 35u/ml as a cutoff, the positivity according to FIGO staging was 9 out of 15cases (60%) in stage I, 4 out of 4 cases(100%) in stage II, 14 out of 16cases (87.5%) in stage III, and 2 out of 2 cases (100%) at stage IV.
6.When the cut off point of CA-125 concentration was decided as 35u/ml, sensitivity, specificity, positive predictive value, and diagnostic efficiency of CA-125 concentration for malignant ovarian tumor were 81.08%, 58.33%, 27.27%, 94.12%, and 56.13% respectively.
Our results suggest that CA-125 assay can be used only as a diagnostic adjunct for discriminating benign from malignant ovarian tumors.

목차 (Table of Contents)

• Ⅰ.서론
• Ⅱ.대상 및 방법
• Ⅲ.연구 결과
• Ⅳ.고찰
• Ⅴ.결론